Cargando…

Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol

BACKGROUND: To compare the efficacy and safety of bioavailable turmeric extract versus paracetamol in patients with knee osteoarthritis (OA). METHODS: In this randomized, non-inferiority, controlled clinical study, patients of knee OA were randomized to receive bioavailable turmeric extract (BCM-95®...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhal, Shubha, Hasan, Nazer, Nirmal, Kirti, Chawla, Rohit, Chawla, Shalini, Kalra, Bhupinder Singh, Dhal, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847013/
https://www.ncbi.nlm.nih.gov/pubmed/33516238
http://dx.doi.org/10.1186/s13063-021-05053-7
_version_ 1783644852014022656
author Singhal, Shubha
Hasan, Nazer
Nirmal, Kirti
Chawla, Rohit
Chawla, Shalini
Kalra, Bhupinder Singh
Dhal, Anil
author_facet Singhal, Shubha
Hasan, Nazer
Nirmal, Kirti
Chawla, Rohit
Chawla, Shalini
Kalra, Bhupinder Singh
Dhal, Anil
author_sort Singhal, Shubha
collection PubMed
description BACKGROUND: To compare the efficacy and safety of bioavailable turmeric extract versus paracetamol in patients with knee osteoarthritis (OA). METHODS: In this randomized, non-inferiority, controlled clinical study, patients of knee OA were randomized to receive bioavailable turmeric extract (BCM-95®) 500 mg capsule two times daily or paracetamol 650 mg tablet three times daily for 6 weeks. The primary outcome measure was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The secondary outcome measures were WOMAC total, WOMAC stiffness, and WOMAC physical function scores. Responder analysis of individual patients at different levels (≥ 20%, ≥ 50%, and ≥ 70%) for WOMAC score was calculated. TNF alpha and CRP levels were evaluated and adverse events (AE) were also recorded. RESULTS: Seventy-one and seventy-three knee OA patients, respectively in bioavailable turmeric extract and paracetamol groups, completed the study. Non-inferiority (equivalence) test showed that WOMAC scores were equivalent in both the groups (p value < 0.05) in all the domains within the equivalence limit defined by effect size (Cohen’s d) of 0.5 whereas CRP and TNF-α were better reduced with turmeric extract than paracetamol. After 6 weeks of treatment, WOMAC total score, pain, stiffness, and function scores got a significant improvement of 23.59, 32.09, 28.5, and 20.25% respectively with turmeric extract. In the turmeric extract group, 18% of patients got more than 50% improvement and 3% of patients got more than 70% improvement in WOMAC pain and function/stiffness score and none of the patients in the paracetamol group met the criteria. CRP and TNF-α got significantly reduced (37.21 and 74.81% respectively) in the turmeric extract group. Adverse events reported were mild and comparatively less in the turmeric extract group (5.48%) than in the paracetamol group (12.68%). CONCLUSION: The results of the study suggest that bioavailable turmeric extract is as effective as paracetamol in reducing pain and other symptoms of knee osteoarthritis and found to be safe and more effective in reducing CRP and TNF-α. TRIAL REGISTRATION: Clinical Trials Registry – India CTRI/2017/02/007962. Registered on 27 February 2017 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05053-7.
format Online
Article
Text
id pubmed-7847013
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78470132021-02-01 Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol Singhal, Shubha Hasan, Nazer Nirmal, Kirti Chawla, Rohit Chawla, Shalini Kalra, Bhupinder Singh Dhal, Anil Trials Research BACKGROUND: To compare the efficacy and safety of bioavailable turmeric extract versus paracetamol in patients with knee osteoarthritis (OA). METHODS: In this randomized, non-inferiority, controlled clinical study, patients of knee OA were randomized to receive bioavailable turmeric extract (BCM-95®) 500 mg capsule two times daily or paracetamol 650 mg tablet three times daily for 6 weeks. The primary outcome measure was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The secondary outcome measures were WOMAC total, WOMAC stiffness, and WOMAC physical function scores. Responder analysis of individual patients at different levels (≥ 20%, ≥ 50%, and ≥ 70%) for WOMAC score was calculated. TNF alpha and CRP levels were evaluated and adverse events (AE) were also recorded. RESULTS: Seventy-one and seventy-three knee OA patients, respectively in bioavailable turmeric extract and paracetamol groups, completed the study. Non-inferiority (equivalence) test showed that WOMAC scores were equivalent in both the groups (p value < 0.05) in all the domains within the equivalence limit defined by effect size (Cohen’s d) of 0.5 whereas CRP and TNF-α were better reduced with turmeric extract than paracetamol. After 6 weeks of treatment, WOMAC total score, pain, stiffness, and function scores got a significant improvement of 23.59, 32.09, 28.5, and 20.25% respectively with turmeric extract. In the turmeric extract group, 18% of patients got more than 50% improvement and 3% of patients got more than 70% improvement in WOMAC pain and function/stiffness score and none of the patients in the paracetamol group met the criteria. CRP and TNF-α got significantly reduced (37.21 and 74.81% respectively) in the turmeric extract group. Adverse events reported were mild and comparatively less in the turmeric extract group (5.48%) than in the paracetamol group (12.68%). CONCLUSION: The results of the study suggest that bioavailable turmeric extract is as effective as paracetamol in reducing pain and other symptoms of knee osteoarthritis and found to be safe and more effective in reducing CRP and TNF-α. TRIAL REGISTRATION: Clinical Trials Registry – India CTRI/2017/02/007962. Registered on 27 February 2017 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05053-7. BioMed Central 2021-01-30 /pmc/articles/PMC7847013/ /pubmed/33516238 http://dx.doi.org/10.1186/s13063-021-05053-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Singhal, Shubha
Hasan, Nazer
Nirmal, Kirti
Chawla, Rohit
Chawla, Shalini
Kalra, Bhupinder Singh
Dhal, Anil
Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title_full Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title_fullStr Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title_full_unstemmed Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title_short Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
title_sort bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847013/
https://www.ncbi.nlm.nih.gov/pubmed/33516238
http://dx.doi.org/10.1186/s13063-021-05053-7
work_keys_str_mv AT singhalshubha bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT hasannazer bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT nirmalkirti bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT chawlarohit bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT chawlashalini bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT kalrabhupindersingh bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol
AT dhalanil bioavailableturmericextractforkneeosteoarthritisarandomizednoninferioritytrialversusparacetamol